Regenxbio Inc (RGNX)
9.75
+0.57
(+6.21%)
USD |
NASDAQ |
Nov 22, 13:36
Regenxbio Shareholders Equity (Quarterly): 301.42M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 301.42M |
| June 30, 2024 | 348.27M |
| March 31, 2024 | 390.67M |
| December 31, 2023 | 311.74M |
| September 30, 2023 | 363.10M |
| June 30, 2023 | 405.86M |
| March 31, 2023 | 465.14M |
| December 31, 2022 | 516.20M |
| September 30, 2022 | 563.82M |
| June 30, 2022 | 630.52M |
| March 31, 2022 | 689.67M |
| December 31, 2021 | 764.30M |
| September 30, 2021 | 461.41M |
| June 30, 2021 | 507.24M |
| March 31, 2021 | 554.50M |
| December 31, 2020 | 377.75M |
| September 30, 2020 | 415.66M |
| June 30, 2020 | 397.86M |
| March 31, 2020 | 420.15M |
| December 31, 2019 | 450.20M |
| Date | Value |
|---|---|
| September 30, 2019 | 468.40M |
| June 30, 2019 | 494.59M |
| March 31, 2019 | 487.05M |
| December 31, 2018 | 508.85M |
| September 30, 2018 | 494.06M |
| June 30, 2018 | 317.22M |
| March 31, 2018 | 299.34M |
| December 31, 2017 | 183.03M |
| September 30, 2017 | 194.65M |
| June 30, 2017 | 211.70M |
| March 31, 2017 | 212.90M |
| December 31, 2016 | 161.74M |
| September 30, 2016 | 180.23M |
| June 30, 2016 | 196.18M |
| March 31, 2016 | 208.60M |
| December 31, 2015 | 216.81M |
| September 30, 2015 | 221.81M |
| June 30, 2015 | 82.63M |
| December 31, 2014 | -5.698M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
301.42M
Minimum
Sep 2024
764.30M
Maximum
Dec 2021
466.77M
Average
435.17M
Median
Shareholders Equity (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 660.94M |
| EyePoint Pharmaceuticals Inc | 218.73M |
| Cassava Sciences Inc | 166.64M |
| Vertex Pharmaceuticals Inc | 15.63B |
| Sarepta Therapeutics Inc | 1.221B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 519.11M |
| Total Liabilities (Quarterly) | 217.70M |
| Current Ratio | 3.051 |